FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Strong Stewart W					2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]								(Ch	eck all appl Direct	,		10% Ov	vner		
(Last) 125 SUN	(Fi MMER STR	,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/16/2022								X Officer (give title Other (specify below) President, Global Hospital								
(Street) BOSTON MA 02110				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(S	tate)	(Zip)													Perso	n ———			
		Tab	le I - No	n-Deriv	ative	Se	curitie	s Ac	qui	ired, l	Disp	osed o	of, or I	3ene	eficial	ly Owne	d			
''' ''' '			2. Trans Date (Month/	Ex Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)), T	Transaction Di		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			(A) or 3, 4 and	Benefic Owned	es Fo ially (D) Following (I)		n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									[Code	v	Amount	Amount (A) or (D)		Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)
Common Stock 05/				05/10	6/2022	/2022			Α		4,123	4,123 ⁽¹⁾ A		(2)	16,	16,840(3)		D		
		7	able II -									sed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemde Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				Expi	6. Date Exercisab Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title	O N O	lumber					
Non- qualified Stock Option (Right to Buy)	\$57.6	05/16/2022			A		9,641			(4)	05	5/16/2029	Commo Stock		9,641	\$0	9,641	l	D	

Explanation of Responses:

- 1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- 2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- 3. This number includes unvested RSUs previously reported.
- 4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

<u>/s/ Thomas V. Powers,</u> attorney-in-fact for Mr. Strong

05/18/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.